New Appointment to the Scientific Advisory Committee at Egenix, Inc. - Hawaii News Now - KGMB and KHNL

New Appointment to the Scientific Advisory Committee at Egenix, Inc.

Information contained on this page is provided by an independent third-party content provider. WorldNow and this Station make no warranties or representations in connection therewith. If you have any questions or comments about this page please contact pressreleases@worldnow.com.

SOURCE Egenix, Inc.

MILLBROOK, N.Y., May 16, 2014 /PRNewswire/ -- Donald Fresne, President and CEO of Egenix, Inc. is pleased to announce the appointment of Hans-Guido Wendel, MD, to its Scientific Advisory Committee.

Dr. Wendel, a graduate of the University of Aachen, Germany, trained in clinical hemato-oncology in Germany, performed research at Cold Spring Harbor and presently holds a tenure-track position at Sloan Kettering Institute NYC focusing on the genetics of lymphatic cancer and initially identified oncogenic role of the eIF4E translation factor in that cancer.

We at Egenix are delighted to have Dr. Wendel aboard and feel confident that he will make significant contributions to Egenix and to the advancement of science and medicine.

Egenix is a privately held, New York-based biotechnology company focused on the development of innovative cancer therapeutics. The company's therapeutic platform technology consists of small molecule drugs applicable for the treatment and prevention of a broad spectrum of cancers, autism, and Alzheimer's. Our lead drug candidates inhibit the "translation initiation factor" eIF4E, specifically blocking production of multiple cancer promoting proteins and promoting apoptosis (programmed cell death) and upregulation of tumor suppressor genes. The company licensed this technology from Harvard Medical School in 2007. eIF4E is an attractive cancer therapeutic target because every function necessary for cancer growth and metastasis is influenced or mediated be a gene product that is regulated by this translation initiation factor. Data from human cancer xenograft studies using two of our lead compounds tested against breast cancer and melanoma demonstrated 100% tumor inhibition and 20% to 30% tumor reduction. For more information visit www.egenixinc.com

©2012 PR Newswire. All Rights Reserved.